Novartis announced that it has entered into a definitive agreement to acquire Avidity Biosciences, a San Diego-based biopharmaceutical company pioneering a new class of RNA-based...
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates announced the Phase 1/2 EXPLORE44™...
